Summary To determine the clinical significance of MRP in patients with colorectal carcinomas, we have studied the expression of the MRP gene by reverse transcription-polymerase chain reaction (RT-PCR) (n=105) and by immunohistochemistry (n=30). MRP mRNA expression was observed in 92 (88%) tumour specimens. Positive MRP staining with monoclonal antibodies QCRL-1 and QCRL-3 was detected in all samples studied with strong staining in seven (23%) and weak staining in 23 (77%) specimens. Strong MRP staining in these samples did not appear to be related to the age and sex of the patients, localization of the primary tumour, histological grade, tumour size, lymph node metastasis, distant metastasis and tumour stage. Strong MRP staining was not associated with MDR1 RNA or P-glycoprotein (P-gp) expression. Kaplan-Meier curves revealed that overall survival of patients with strong MRP-staining tumours was similar to the survival of patients with weak-staining tumours. These data indicate that the MRP gene is expressed in primary colorectal carcinomas but is neither related to known prognostic factors nor a prognostic factor by itself.
Drug resistance remains a major problem in patients with colorectal carcinomas, which are usually intrinsically resistant to anti-cancer drugs. The clinically relevant mechanisms of drug resistance are currently under investigation. One important mechanism may be the multidrug-resistance phenotype (Pastan and Gottesman, 1987; Gottesman and Pastan, 1988 ; Simon and Schindler, 1994) . Multidrug resistance (MDR) is the term for the resistance against a variety of hydrophobic natural compounds, including several anti-cancer drugs (Pastan and Gottesman, 1987) .
MDR is caused in part by overexpression of the MDRJ gene (Goldstein et al, 1989) . This gene codes for P-glycoprotein (P-gp), a 170-kDa transmembrane protein, which may function as an energy-dependent drug efflux pump (Pastan and Gottesman, 1987; Gottesman and Pastan, 1988) . Besides the 'active drug pump model', the 'altered partitioning model' is discussed. The latter model proposes that altered sequestration of anti-cancer drugs and other compounds is the indirect result of perturbations in the character and/or magnitude of eukaryotic plasma membrane electrochemical potential caused by P-gp overexpression (Roepe, 1995) . Expression of MDR] mRNA and P-gp was demonstrated in 65% and 68% of primary colorectal carcinomas respectively (Weinstein et al, 1991; Pirker et al, 1993) . Although MDR was previously thought to be predominantly caused by the expression of the MDRJ gene, it is now increasingly believed to be caused by other mechanisms also (Roepe et al, 1993; Simon and Schindler, 1994; Filipits et al, 1996a ).
P-gp-mediated MDR (Cole et al, 1992; Barrand et al, 1994) . This 190-kDa membrane protein is encoded by the MRP gene, which has recently been cloned (Cole et al, 1992) . Transfection studies have demonstrated that overexpression of human MRP confers a multidrug-resistance phenotype Kruh et al, 1994; Zaman et al, 1994) . MRP is believed to be involved in the ATP-dependent transport of cysteinyl leukotrienes (e.g. LTC4) and other glutathione-S-conjugates (Loe et al, 1996) . MRP has also been suggested to be involved in the transport of vincristine in the presence of reduced glutathione (Loe et al, 1996) . However, the exact mechanisms by which MRP mediates resistance to anticancer drugs remains to be determined.
The aim of our present study was, firstly, to determine the expression of the MRP gene in primary colorectal carcinomas in order to evaluate the clinically active mechanisms of MDR in these tumours further, and, secondly, to assess its association with other clinical parameters, including the survival of patients.
PATIENTS AND METHODS Patients
Between 1988 and 1995, 105 patients with colorectal carcinomas were admitted to this study. Sixty-five patients had been included in a previous study (Pirker et al, 1993) . The patients were treated at the Surgical Department of the General Hospital of Wiener Neustadt, Austria.
Forty-two patients received adjuvant chemotherapy with 5-fluorouracil and leucovorin as described (Pirker et al, 1993) . During metastatic disease, patients were usually treated with 5-fluorouracil with or without leucovorin and occasionally also with cisplatin and drugs to which P-gp overexpression may confer resistance (mitoxantrone and mitomycin C).
Tumour specimens and cell lines Colorectal carcinoma specimens and adjacent normal tissue specimens were obtained by surgery and stored at -80°C until use. Samples were graded for histological type and Dukes' stage according to standard criteria. Peripheral blood mononuclear cells were obtained from healthy volunteers by Ficoll-Paque gradient centrifugation. KB-3-1 and KB-8-5 cells (provided by Drs I Pastan and M Gottesman, National Cancer Institute, Bethesda, MD, USA) were grown as described (Pirker et al, 1991) . Cytospins of Cl and T5 cells as well as cDNAs synthesized from RNA that had been isolated from these cells were kindly provided by Drs S Cole and R Deeley (Queen's University, Kingston, Canada).
Analysis of gene expression by RT-PCR
Total RNA was extracted from tumour specimens by means of RNAzol (Cinna Scientific, Cincinnati, OH, USA) and quantitated spectrophotometrically. MRP RNA was determined as described recently (Filipits et al, 1996b) .
Briefly, 5-10 gg of total RNA was used for cDNA synthesis using Moloney murine leukaemia virus reverse transcriptase (Promega) in a total volume of 50 gl. After 1 h incubation at 37°C, 5 min at 95°C and a quick chill to 4°C, cDNA was stored at -20°C until use.
The cDNA reaction mixture (5-10 tl) was used for amplification of specific DNA sequences. A total of 30-35 cycles at 95°C for 25 s, 57°C for 30 s and 73°C for 1 min and a quick chill to 4'C in a 9600 thermocycler (Perkin Elmer Cetus, Emeryville, CA, USA) were performed. Samples, which were MRP mRNA negative after 30 cycles, were re-evaluated with 35 cycles under otherwise unchanged conditions. In this study, all oligonucleotides used as primers were synthesized by Fa. Biomedica (Vienna, Austria). The primers were chosen as follows: 5'-TGAAG-GACTTCGTGTCAGCC-3' (forward primer; residues 4419-4438) and 5'-GTCCATGATGGTGTTGAGCC-3' (reverse primer; residues 4656-4675) of the MRP gene (Zaman et al, 1993) , 5'-ACCCCCACTGAAAAAGATGA-3' (forward primer; residues 1544-1563) and 5'-ATCTTCAAACCTCCATGATG-3'
( r e v e r s e p r i m e r residues 2253-2262 and 3508-3517) of the f32-microglobulin (J32-m) gene (Noonan et al, 1990) , and 5'-CCCATCATTG-CAATAGCAGG-3' (forward primer; residues 2596-2615) and 5'-GTTCAAACTTCTGCTCCTGA-3' (reverse primer; residues 2733-2752) of the MDR] gene (Noonan et al, 1990) . All corresponding pairs of the primers spanned an intron to control against contamination by amplification of genomic DNA sequences. The 
Immunohistochemical analysis
Monoclonal antibodies QCRL-1 and QCRL-3 (kindly provided by Drs S Cole and R Deeley, Queen's University, Kingston, Canada), which recognize different epitopes of MRP , as well as monoclonal antibodies C219 and MRK16, which recognize different epitopes of P-gp, were used for immunohistochemistry as described previously (Filipits et al, 1996b) .
Cryostat sections (4 jum) of the colorectal carcinoma specimens were prepared. Serial sections were used for MRP and P-gp . Drugsensitive KB-3-1 and multidrug-resistant KB-8-5 cells served as negative and positive controls for P-gp expression respectively. Immunostained slides were independently examined by two observers who had no previous knowledge of the clinical outcome of the patients. MRP and P-gp immunostaining were evaluated and scored separately.
Survival analysis
Durations of overall survival (OS) were estimated according to Kaplan and Meier (1958) . OS was measured from the time of diagnosis until the time of death or in the case of censored patients until the time of the last control.
Statistical analysis
Frequencies were examined by chi-square tests. In addition, Kruskal-Wallis tests were performed. Survival curves were compared by the Wilcoxon test. RESULTS MRP expression in colorectal carcinoma specimens MRP mRNA expression of primary colorectal carcinoma specimens (n= 105) was determined by RT-PCR. Drug-sensitive Cl and drug-resistant T5 cells were used as negative and positive controls respectively. In addition, peripheral blood mononuclear cells served as positive controls. The P2-m gene, which was coamplified with the MRP gene, was used as an internal control. Ninety-two (88%) colorectal carcinomas did express MRP mRNA (Table 1) . Thirteen carcinomas were negative for MRP mRNA (Table 1) and remained negative when the number of RT-PCR cycles was raised (1997) 75(2) (n=23) or strong MRP staining (n= according to Kaplan and Meier (1958) . Statistical com curves was done by the Wilcoxon test determined by RT-PCR and was detected ir (Table 1) . P-gp expression was also studied cally by means of the monoclonal antibodies respectively, and was found to be positive i staining) and 47% (17% strong staining) of th respectively (Table 1) . No significant correl and MDRJ mRNA or P-gp expression was ob MRP in relation to clinical parameters Next, we evaluated the association of MRP g clinical parameters. Histological examinatior cinomas in all cases (data not shown). MRP gc tumours did not appear to be related to sex an4 localization and size of the primary tumour tumour infiltration of the lymph nodes, dis tumour stage (Table 2) .
To evaluate whether strong MRP staining prognostic value, Kaplan-Meier analysis of performed in 30 patients. At a median follo overall survival of patients with weak-staining to the survival of patients with strong-staining
DISCUSSION
In the present study, expression of MRP RNA of the primary colorectal carcinomas. MRI immunohistochemistry, was expressed in all with strong staining in 23% of the samples. TI that the MRP gene might contribute to the intr of colorectal carcinomas. Previously, expre gene, which was seen in approximately two colorectal carcinomas, was thought to be the nism of MDR in these tumours (Goldstein et a al, 1991; Pirker et al, 1993; Sinicrope et al, 1' of strong MRP-staining tumours is consist report on MRP expression in four out of 12 (3. nomas (Nooter et al, 1995) . The percenta tumours in our study (40% and 47%) is also si ages previously reported (Weinstein et al, 199 De Angelis et al, 1995) .
Strong MRP staining did not appear to be related to size of the primary tumour, lymph node involvement, distant metastasis, tumour stage and survival of the patients (Table 2) (Thomas et al, 1994) . Secondly, a functionally active MRP gene was most likely without clinical impact because most patients were not treated with MDR drugs and because the activity 7) was calculated of 5-fluorouracil is not affected by MRP. Finally, a type II statisiparison between the tical error cannot be excluded. Therefore, it might be worthwile to confirm these results in a larger study population.
In one report, P-gp expression was observed predominantly in invasively growing tumour cells, suggesting that P-gp expression is associated with local tumour aggressiveness (Weinstein et al, n 83 (83%) samples 1991) . Despite these findings however, neither MDRJ mRNA nor immunohistochemi-P-gp expression of the tumours was of prognostic value in patients s C219 and MRK16 with colorectal carcinomas (Mayer et al, 1993; Pirker et al, 1993) . in 40% (13% strong No correlation between MRP gene expression and MDRJ gene ie tumour specimens expression was observed (Table 2 ). In contrast to these results, ation between MRP sequential coexpression of the MRP and the MDR] gene was iserved (Table 2) . detected in etoposide-selected H69 small-cell lung cancer cells (Brock et al, 1995) . Recently, one mutant p53 has been shown to stimulate the MDRJ promoter in vitro, whereas wild-type p53 represses its ;ene expression with activity (Chin et al, 1992) . In colorectal carcinoma specimens, l revealed adenocarhowever, P-gp expression was independent of p53 expression or ene expression of the the incidence of p53 mutations (De Angelis et al, 1995), d age of the patients, suggesting that mutant p53 does not induce overexpression of histological grade, P-gp in colorectal carcinomas. MRP gene expression correlated stant metastasis and with amplification and overexpression of the n-myc oncogene in childhood neuroblastoma (Bordow et al, 1994 ; Norris et al, of the tumours is of 1996). Thus, future studies will have to define further the relationoverall survival was ship between drug resistance genes and oncogenes or tumourow-up of 39 months, suppressor genes in colorectal carcinomas. tumours was similar MRP gene expression could be involved in the clinically welltumours (Figure 1) . known intrinsic resistance of colorectal carcinomas to MDR drugs. Because in vitro MRP is believed to be involved in the transport of certain anti-cancer drugs, including anthracyclines and vinca alkaloids Grant et al, 1994) , it is anticwas detected in 88% ipated that this function also contributes to the inactivity of these P, as determined by drugs in the treatment of colorectal carcinomas. Expression of tumour specimens, MRP might also be one of the reasons why previous clinical trials hese findings suggest with resistance modifiers of the MDRJ gene (Pirker et al, 1990;  rinsic drug resistance Twentyman, 1992) failed in patients with colorectal carcinomas ssion of the MDR] and other tumours (Lehnert, 1993; Milroy et al, 1993) . out of three primary
In conclusion, multidrug resistance in colorectal carcinomas is a predominant mechacomplex phenomenon probably involving both the MRP gene and .1, 1989; Weinstein et the MDR] gene. Future studies will have to address their regula-)94). Our percentage tion of expression and quantitative contribution to resistance to tent with the recent anti-cancer drugs. The presence of MRP gene expression will 3%) colorectal carcialso have to be considered in the planning of future clinical trials ge of P-gp-positive with drug resistance modifiers. In addition, other mechanisms imilar to the percentinvolved in the MDR of cell lines will also have to be studied in 1; Mayer et al, 1993;  colorectal carcinomas (Beck, 1989; Simon and Schindler, 1994) .
Only knowledge of all clinically important mechanisms of drug British Journal of Cancer (1997) 75 (2), [208] [209] [210] [211] [212] resistance might eventually enable clinicians to design ways to overcome drug resistance and, thereby, improve the outcome of chemotherapy in patients with colorectal carcinomas.
